Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer
Phase Not Applicable
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Establishment of a registry by which to census all patients treated with adjuvant hormone blockade for previous breast cancer in order to evaluate in future studies the trend of bone mass and its relationship to laboratoristic indices inherent in calcium metabolism, and the prevalence and incidence of fractures.

Design

Study type: Observational Observational model: Other Time perspective: Other

Primary Outcomes

  • Establishment of a Registry for Patients Treated with Adjuvant Hormone Blockade for Breast Cancer: Evaluation of Bone Mass, Calcium Metabolism Indices, and Fracture Incidence (through study completion, an average of 15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-12-18
Completion: 2039-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Principal Investigators:
  • Uberto Pagotto, MD (PRINCIPAL_INVESTIGATOR) - IRCCS Azienda Ospedaliero-Universitaria di Bologna
Contact Information
Study Contact:
Uberto Pagotto, MD
+390512144190
uberto.pagotto@unibo.it
Uberto Pagotto, MD
+390512144190
uberto.pagotto@unibo.it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Uberto Pagotto, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Interventions
N/A
Study Locations (1 sites)
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Bologna 40138 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Patient undergoing adjuvant hormone blockade therapy (aromatase inhibitors, GnRH analogs, tamoxifen) for breast cancer referred by UO Oncology Zamagni * Performed densitometry at UO Radiology Lovato and performed hematochemical tests inherent to mineral metabolism * Informed consent obtained Exclusion Criteria: * none
Conditions Depression/Anxiety
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Mental health among university students has emerged as a significant global issue. Recent meta-analyses reveal that 25% of students experience depressive symptoms and 14% exhibit suicidal behaviors. A study involving 19 universities across 8 countries found that 31.4% reported psychiatric disorders in the past year, particularly major depressive episodes and anxiety disorders. In Chile, research on university mental health is limited. A 2014 study at Universidad Austral reported a 27% prevalence of depression and a 5.3% risk of moderate to severe suicide risk. The "First National Survey of University Mental Health" in 2019 revealed that 46% of students had depressive symptoms, while health surveys from Universidad de los Andes in 2020 and 2022 showed a decrease in these symptoms, although suicide risk remained high. Given this situation, preventive interventions are urgently needed. "Mindfulness-Based Interventions" (MBIs) have shown effectiveness in university settings. Mindfulness, defined by Jon Kabat-Zinn, involves deliberate, non-judgmental attention to the present moment. Programs like "Mindfulness-Based Stress Reduction" (MBSR) have proven effective in reducing symptoms of depression, anxiety, and stress. Studies indicate that MBIs can effectively alleviate mental health symptoms in university populations. Some of the MBIs include "Mindful Mood Balance" (MMB) and "Mindfulness Skills for Students". The latter has shown effectiveness in reducing depressive and anxious symptoms among university students. A 2021 pilot study at Universidad de los Andes on an online 8-session intervention combining mindfulness with cognitive-behavioral techniques yielded positive results in reducing symptoms and enhancing students' quality of life. In the current proposal we want to evaluate the feasibility and acceptability of the "Mindfulness Skills for Students" program delivered in-person by two trained facilitators. Additionally, we want to explore the efficacy of this intervention in reducing depressive, anxious, and stress symptoms among undergraduate students at Universidad de los Andes, using a quasi-experimental study design.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Mindfulness in Students — The mindfulness intervention includes eight 90-minute group sessions held weekly at Universidad de los Andes, co-facilitated by two instructors. One leads the activities, while the other assists with technical aspects, monitors adverse events, and provides participant support. Participants will receive mindfulness worksheets and are required to practice at home for 15 minutes daily. They will have access to an online platform with audiovisual materials to guide their practice and will complete home practice logs online. Skills taught include sitting meditation (focused on breathing, thoughts, emotions, or sensations), body scan meditation, standing meditation, and mindfulness of daily activities. Group discussions will cover topics such as defining mindfulness, managing stress and pain, the difference between mindfulness and being on 'autopilot,' and how perceptions affect stress, as well as the relationship between pain and suffering, and the acceptance of unwanted experiences.

Primary Outcomes

  • Acceptability Assessment (through study completion, an average of 2 year)
  • Feasibility Assessment: Number of participants recruited (through study completion, an average of 2 year)
  • Feasibility Assessment: Recruitment time for completion (through study completion, an average of 2 year)
  • Feasibility Assessment: Evaluation of data collection and results. (through study completion, an average of 2 year)
  • Feasibility Assessment: Evaluation of the acceptability of the intervention (through study completion, an average of 2 year)
  • Client Satisfaction Questionnaire (CSQ-8) (through study completion, an average of 2 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-01
Completion: 2026-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universidad de los Andes, Chile
Contact Information
Study Contact:
Jorge E Gaete, MD, PhD
+56226181000
jgaete@uandes.cl
Valentina Romo
+56984038329
vromo@miuandes.cl
Jorge E Gaete, Md, PhD
+56226181000
jgaete@uandes.cl
Universidad de los Andes
Interventions
  • Behavioral: Mindfulness in Students — The mindfulness intervention includes eight 90-minute group sessions held weekly at Universidad de los Andes, co-facilitated by two instructors. One leads the activities, while the other assists with technical aspects, monitors adverse events, and provides participant support. Participants will receive mindfulness worksheets and are required to practice at home for 15 minutes daily. They will have access to an online platform with audiovisual materials to guide their practice and will complete home practice logs online. Skills taught include sitting meditation (focused on breathing, thoughts, emotions, or sensations), body scan meditation, standing meditation, and mindfulness of daily activities. Group discussions will cover topics such as defining mindfulness, managing stress and pain, the difference between mindfulness and being on 'autopilot,' and how perceptions affect stress, as well as the relationship between pain and suffering, and the acceptance of unwanted experiences.
Study Locations (1 sites)
Universidad de los Andes, Santiago, Santiago Metropolitan 7620086 Chile
Eligibility Criteria
Inclusion Criteria: * Undergraduate students at the Universidad de los Andes. * Aged 18 or older. * Capable of reading and speaking Spanish. * With a score on the PHQ-9 depression scale between 0 and 14. * Have participated in an informational meeting about the study and the implications of the intervention. * Availability to attend 1 weekly session of 90 minutes for 8 consecutive weeks, and time to practice mindfulness exercises at home for at least 15 minutes daily during the intervention period. Exclusion Criteria: * With a PHQ-9 score greater than or equal to 15. * With active suicidality, defined as score ≥ 3 in Columbia suicide severity scale. * Currently undergoing psychiatric treatment for a severe condition, understood as: psychotic disorders and/or substance abuse. * History of hospitalization for psychiatric conditions in the last 2 years. * History of having participated in a previous MBI course, such as: MBCT, MBSR, MMB, among others. * History of sexual abuse in their lifetime.
Conditions Suicide Risk, Major Depressive Disorder ...
Phase PHASE2
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this proof-of-concept clinical trial is to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in a sample of veteran adults with Major Depressive Disorder and elevated suicide risk. The main question it aims to answer is: Is Suvorexant safe, feasible, and tolerable for participants? Participants will: * Take Surovexant every day for four weeks (10mg in the first two weeks and 20mg in the second two weeks) * Visit the medical center at the beginning of the study (week 1), after taking Suvorexant for two weeks (week 3) and following the full Suvorexant dose (week 5) for in-person assessments. * Fill out self-report assessments (remotely) at week 2 (after one week of Suvorexant) and week 4 (after three weeks of Surovexant)

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Suvorexant (dual orexin receptor antagonist) — Veteran patients with Major Depressive Disorder and elevated risk of suicide will receive the FDA-approved drug Suvorexant (brand name: Belsomra), a dual orexin receptor antagonist, for four weeks. Participants will take 10mg of Surovexant nightly for the first two weeks and 20mg of Surovexant nightly for the second two weeks.

Primary Outcomes

  • Implicit Association Tests (IATs) (Weeks 1, 3, and 5)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Marianne Goodman
Collaborators: James J. Peters Veterans Affairs Medical Center
Contact Information
Study Contact:
Marianne Goodman, MD
718-584-9000
Marianne.Goodman@va.gov
James Murrough, MD, PhD
212-585-4640
James.Murrough@va.gov
Interventions
  • Drug: Suvorexant (dual orexin receptor antagonist) — Veteran patients with Major Depressive Disorder and elevated risk of suicide will receive the FDA-approved drug Suvorexant (brand name: Belsomra), a dual orexin receptor antagonist, for four weeks. Participants will take 10mg of Surovexant nightly for the first two weeks and 20mg of Surovexant nightly for the second two weeks.
Study Locations (1 sites)
James J. Peters Veterans Affairs Medical Center, The Bronx, New York 10468 United States
Eligibility Criteria
Inclusion Criteria: * Veteran * At least 18 years of age (up to 70 years) * Primary diagnosis of Major Depressive Disorder as determined by the study psychiatrist and confirmed by the Mini-International Neuropsychiatric Interview (MINI) * Lifetime suicide attempt history and suicidal ideation at baseline as determined by a score ≥2 on the Columbia-Suicide Severity Rating Scale (C-SSRS) Exclusion Criteria: * Clinically significant medical or neurological condition * Current use of strong CYP3A live enzymes or moderate CYP3A inhibitors or strong CYP3A inducers * Current use of digoxin * Currently pregnant, not using contraception, nursing, or trying to become pregnant * Active substance use disorder in the last six months, disorder, or current or past psychotic disorder, bipolar disorder, or obsessive-compulsive disorder * Severe traumatic brain injury * Imminent suicidal or homicidal risk * Free of unstable medical conditions or any contraindication to suvorexant (per FDA prescribing label) as determined by patient interview and review of available medical records.
Conditions Glaucoma, Open-angle, Ocular Hypertensio...
Phase PHASE4
Enrollment 132
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Combination Product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery — iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
  • Procedure: Sham procedure in conjunction with cataract surgery — Sham procedure in conjunction with cataract surgery

Primary Outcomes

  • Change from baseline in mean diurnal IOP (3 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-01-13
Completion: 2027-06
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 132 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Glaukos Corporation
Principal Investigators:
  • Study Director (STUDY_CHAIR) - Glaukos Corporation
Contact Information
Study Contact:
Study Manager
949-739-8749
ClinicalResearch@glaukos.com
idose@glaukos.com
Glaukos Investigator Site
Interventions
  • Combination Product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery — iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
  • Procedure: Sham procedure in conjunction with cataract surgery — Sham procedure in conjunction with cataract surgery
Study Locations (1 sites)
Glaukos Investigator Site, Kenosha, Wisconsin 53142 United States
Eligibility Criteria
Inclusion Criteria: * Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye. * OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery) Exclusion Criteria: * Active corneal inflammation or edema. * Retinal disorders not associated with glaucoma.
Conditions Hepatocellular Carcinoma, Esophageal Var...
Phase PHASE2
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate whether prophylactic endoscopic variceal ligation (EVL) can prevent esophageal variceal bleeding in patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev) therapy. The study will also assess the safety of prophylactic EVL in this population. The main question it aims to answer is: Does prophylactic EVL in high-risk varices reduce the incidence of variceal bleeding to a level similar to that of low-risk varices in HCC patients receiving Atezo/Bev? Participants will: 1. Undergo prophylactic EVL before starting Atezo/Bev therapy (within 2 weeks ± 1 week before the first dose). 2. Start Atezo/Bev therapy 2 weeks (± 1 week) after EVL. 3. Have follow-up endoscopies (EGD) one week after the 3rd, 5th, and 7th doses of Atezo/Bev. If varices improve, no additional intervention is needed. If varices persist or worsen, on-demand EVL will be performed, and Atezo/Bev will continue. This study will help determine if prophylactic EVL should be a standard strategy for managing high-risk varices in HCC patients undergoing Atezo/Bev therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Endoscopic variceal ligation (EVL) — 1. EVL for high-risk varices will be performed by experienced endoscopists, certified in gastroenterological endoscopy, within two weeks prior to the initiation of the Atezo/Bev. 2. A follow-up EGD will be conducted one week after the Atezo/Bev #3. If any of the following criteria are met, additional EVL will not be performed, and anticancer treatment will proceed two weeks later. Otherwise, an additional on-demand EVL session will be conducted: * The esophageal varices have improved to F1 or less. * The red color sign has disappeared. 3. On-demand EVL will be considered after 5th, and 7th consecutive doses of Atezo/Bev, with EGD follow-up performed to assess eligibility. The maximum number of EVL sessions is limited to three sessions.

Primary Outcomes

  • The incidence of esophageal variceal bleeding at 6 months (From the first Atezo/Bev treatment date until the date of first esophageal varix bleeding, Atezo/Bev treatment discontinuation, or last follow-up, whichever came first, assessed up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-05-28
Completion: 2029-03-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Asan Medical Center
Collaborators: Seoul National University Hospital, Hanyang University, Samsung Medical Center, National Cancer Center, Korea, Seoul National University Bundang Hospital
Principal Investigators:
  • Jihyun An, MD, PhD (STUDY_DIRECTOR) - Gastroenterology and Hepatology, Hanyang University College of Medicine, Guri, Republic of Korea
Contact Information
Study Contact:
Ju Hyun Shim, MD, PhD
+82-2-3010-3190
s5854@amc.seoul.kr
Jiwon Yang, MD
+82-2-3010-0452
ryanghyun90@gmail.com
Ju Hyun Shim, MD, PhD
+82-2-3010-319
s5854@amc.seoul.kr
Liver cancer center, Asan Medical Center
Interventions
  • Procedure: Endoscopic variceal ligation (EVL) — 1. EVL for high-risk varices will be performed by experienced endoscopists, certified in gastroenterological endoscopy, within two weeks prior to the initiation of the Atezo/Bev. 2. A follow-up EGD will be conducted one week after the Atezo/Bev #3. If any of the following criteria are met, additional EVL will not be performed, and anticancer treatment will proceed two weeks later. Otherwise, an additional on-demand EVL session will be conducted: * The esophageal varices have improved to F1 or less. * The red color sign has disappeared. 3. On-demand EVL will be considered after 5th, and 7th consecutive doses of Atezo/Bev, with EGD follow-up performed to assess eligibility. The maximum number of EVL sessions is limited to three sessions.
Study Locations (1 sites)
Liver cancer center, Asan Medical Center, Seoul, Song-pa 05505 South Korea
Eligibility Criteria
Inclusion Criteria: * Patients aged 19 years or older and under 80 years. * Patients with liver function are classified as Child-Pugh Class A. * Barcelona Clinic Liver Cancer stage C patients with no prior systemic anticancer therapy for hepatocellular carcinoma. * Patients with an Eastern Cooperative Oncology Group performance score of 0-1. * Adequate Hematologic and Liver Function: A. Hemoglobin: ≥ 9.0 g/dL B. Absolute Neutrophil Count : ≥ 1,000/mm³ C. Platelet Count: ≥ 70,000/μL D. Prothrombin Time: ≥ 70% (or Prothrombin Time INR ≤ 1.2) * Patients with upper gastrointestinal endoscopy performed within six months prior to the start of anticancer treatment. * No plans for breastfeeding, and if of childbearing potential, using contraception or no plans for spouse's pregnancy or practicing contraception. * Patients who have received an explanation of the treatment purpose and methods and have provided informed consent for the treatment. Exclusion Criteria: * Participants who have previously received systemic anticancer therapy for advanced hepatocellular carcinoma. * Patients with intrahepatic tumor involvement of 50% or more. * Patients with tumor thrombus in the main portal vein or both first-order branches (Vp4). * Patients with a prior history of liver transplantation. * with uncontrolled malignant tumors other than HCC at the time of enrollment (participation is allowed if disease-free survival exceeds two years). * Patients with uncontrolled or serious underlying diseases requiring treatment. * Patients with a history of esophageal or gastric variceal bleeding. * Previous Variceal Treatments: Patients who have undergone any of the following treatments for variceal bleeding: A. Endoscopic Variceal Obliteration (EVO) B. EVL C. Transjugular Intrahepatic Portosystemic Shunt (TIPS) D. Percutaneous Approach for Retrograde Transvenous Obliteration (PARTO) E. Surgical procedures * Patients who have used anticoagulants or antiplatelet agents within one week prior to the study. * Presence of grade 2 or higher isolated gastric varices or Red Color Signs confirmed by baseline endoscopy (EGD). * Patients who are pregnant. * Patients who are unable to understand or provide written informed consent. * Patients deemed unsuitable for clinical study participation based on the investigator's judgment.
Conditions Primary Insomnia
Phase NA
Enrollment 96
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The classical literature combined with modern medicine to select acupoints, in order to intervene in the autonomic nerve function of the superior cervical sympathetic ganglion as an opportunity, put forward the meridian acupoints mainly to reconcile the head orifices Ying Wei, acupuncture treatment of primary insomnia clinical research. Heart rate variability ( HRV ), Pittsburgh sleep quality index ( PSQI ), polysomnography ( PSG ) and the MOS item short from health survey ( SF-36 ) were observed. Insomnia Severity Index ( ISI ), Dysfunctional Beliefs and Attitudes about Sleep Scale 16 ( DBAS-16 ), GABA, Glx and other secondary indicators were used to clarify the clinical short-term and long-term efficacy of different acupoints in the treatment of patients with primary insomnia and the intervention effect on HRV.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Acupuncture — acupuncture Baihui, Sishencong ; acupuncture bilateral Qimen, Zhangmen, Hegu, Taichong, reinforcing and reducing, until the acid swelling is obvious,stopped ferforming acupuncture, the needle was retained for 30 min.
  • Device: Acupuncture — (1)Acupuncture bilateral Tianrong points, obliquely 45 ± 5 ° backward, 1-1.5 inch deep, reinforcing and reducing horizontally, and stop the needle when the auricle has a heat sensation ; (2)Acupuncture at bilateral Tianyou points, pointing to the tip of the nose, with a depth of 0.5-1 inches, flat reinforcing and reducing, until the sense of soreness and distension obviously stops, and the needle is retained for 30 minutes.

Primary Outcomes

  • Sleep quality measured by Pittsburgh sleep quality index ( PSQI) (Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.)
  • Quality of life measure by 36-item short form health survey(SF-36) (Before treatment, 4 weeks of treatment, and 4 weeks after the end of treatment, three time points were observed.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 96 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chuanlong Zhou
Contact Information
Study Contact:
Zhou CL Zhou Chuanlong
15868486255
471388079@qq.com
Zhou CL Zhou Chuanlong
15868486255
471388079@qq.com
The Third Affiliated Hospital of Zhejiang Chinese Medical University
Interventions
  • Device: Acupuncture — acupuncture Baihui, Sishencong ; acupuncture bilateral Qimen, Zhangmen, Hegu, Taichong, reinforcing and reducing, until the acid swelling is obvious,stopped ferforming acupuncture, the needle was retained for 30 min.
  • Device: Acupuncture — (1)Acupuncture bilateral Tianrong points, obliquely 45 ± 5 ° backward, 1-1.5 inch deep, reinforcing and reducing horizontally, and stop the needle when the auricle has a heat sensation ; (2)Acupuncture at bilateral Tianyou points, pointing to the tip of the nose, with a depth of 0.5-1 inches, flat reinforcing and reducing, until the sense of soreness and distension obviously stops, and the needle is retained for 30 minutes.
Study Locations (1 sites)
The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 321000 China
Eligibility Criteria
Inclusion Criteria: * In line with the diagnostic criteria of insomnia of liver depression and spleen deficiency type in traditional Chinese medicine : * In line with the Western diagnostic criteria for insomnia ; * 18 ≤ age ≤ 40 years old, male or female ; * patients with a course of more than two weeks ; Note: The above criteria must be met for inclusion in this study. Exclusion Criteria: * Insomnia caused by a variety of organic diseases, neurological or psychiatric disorders * Pregnancy, lactation or drug allergy * There are more serious primary diseases such as cardiovascular and cerebrovascular diseases, gastrointestinal diseases, endocrine system diseases, or psychiatric patients. * Patients with coagulation dysfunction and bleeding tendency.
Conditions Breast Neoplasms, Breast Carcinoma, Brea...
Phase NA
Enrollment 180
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this phase III randomized controlled trial (PRADAIIBE) is to assess if preoperative radiation therapy (Preop-RT) combined with immediate breast reconstruction (IBR) can safely improve both aesthetic and quality of life outcomes in breast cancer patients, compared to the standard of care (SoC) therapy consisting of post-mastectomy radiation therapy (PMRT) and delayed/immediate breast reconstruction, in a population of breast cancer patients with an indication of mastectomy and PMRT. The following hypotheses and outcomes will be assessed at the primary endpoint of 1 year of follow-up: * Efficacy: Does Preop-RT+IBR lead to a higher BREAST-Q satisfaction with breasts score (primary endpoint), EQ-5D-5L VAS score , EQ-5D-5L Index score, AIS-Total Aesthetic Score, or a shorter treatment duration compared to SoC? * Safety: Does Preop-RT+IBR lead to an increase in adverse events (general or surgical), a lower rate of pathologic Complete Response (pCR), or worse survival outcomes compared to SoC? \[Note: this study was not powered as a non-inferiority trial, all outcomes will be pooled internationally with parallel studies\] Eligible and consenting participants will undergo screening and baseline assessments. They will then be randomised between experimental (Preop-RT+IBR) and control (SoC) groups, in a 1:1 stratified variable block size design. Follow-up will take place at 3 months, 1, 2, 5, and 10 years after the last study treatment. At baseline and during each follow-up visit each participant will complete the Breast Q 'satisfaction with breasts' and EQ-5D-5L scales, photographs will be taken. During follow-up pCR will be assessed if applicable, adverse events will be registered, and oncological follow-up will be recorded.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Preoperative radiotherapy — In this study patients assigned to the experimental treatment arm will receive preoperative radiation therapy instead of postoperative radiation therapy (PMRT). This preoperative radiation therapy will be administered according to the standard of care (SoC) principles for PMRT and Whole Breast Radiation Therapy (WBRT) as defined by international guidelines.
  • Radiation: Postoperative radiotherapy — Standard of care (SoC) postoperative radiotherapy, as defined by international guidelines.
  • Procedure: Immediate breast reconstruction — In the experimental arm of the PRADAIIBE, the participants will undergo immediate breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery. Using one of the following primary techniques: 1) Autologous tissue reconstruction ; 2) Breast implant based reconstruction; 3) Combined autologous tissue and breast implant reconstruction. These techniques can take place in a single phase, or in a two-phased (tissue expander) approach. Adjuvant techniques (e.g.: lipofilling, mesh, ADM etc.) could be added.
  • Procedure: Immediate or delayed breast reconstruction — In the standard arm of the PRADAIIBE, the participants will undergo immediate or delayed breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery (immediate), or at a later time (delayed). Using one of the following primary techniques: 1) Autologous tissue reconstruction ; 2) Breast implant based reconstruction; 3) Combined autologous tissue and breast implant reconstruction. These techniques can take place in a single phase, or in a two-phased (tissue expander) approach. Adjuvant techniques (e.g.: lipofilling, mesh, ADM etc.) could be added.

Primary Outcomes

  • Patient's satisfaction with breasts. (Measured at 3 months, 1year, 2 years, 5 years and 10 years after last locoregional treatment. Primary endpoint: 1 year after LST.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-20
Completion: 2038-02-20
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Research Antwerp
Collaborators: Ziekenhuis aan de Stroom, Iridium netwerk
Principal Investigators:
  • Melanie Machiels, MD, PhD (PRINCIPAL_INVESTIGATOR) - Iridium netwerk
Contact Information
Study Contact:
Tom Quisenaerts, MD
+3234433759
Tom.quisenaerts@zas.be
Isabelle Nietvelt
+32 3 821 30 00
isabelle.nietvelt@uza.be
Universitair Ziekenhuis Antwerpen (UZA)
Christophe Van Berckelaer, MD
Universitair Ziekenhuis Antwerpen (UZA)
Interventions
  • Radiation: Preoperative radiotherapy — In this study patients assigned to the experimental treatment arm will receive preoperative radiation therapy instead of postoperative radiation therapy (PMRT). This preoperative radiation therapy will be administered according to the standard of care (SoC) principles for PMRT and Whole Breast Radiation Therapy (WBRT) as defined by international guidelines.
  • Radiation: Postoperative radiotherapy — Standard of care (SoC) postoperative radiotherapy, as defined by international guidelines.
  • Procedure: Immediate breast reconstruction — In the experimental arm of the PRADAIIBE, the participants will undergo immediate breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery. Using one of the following primary techniques: 1) Autologous tissue reconstruction ; 2) Breast implant based reconstruction; 3) Combined autologous tissue and breast implant reconstruction. These techniques can take place in a single phase, or in a two-phased (tissue expander) approach. Adjuvant techniques (e.g.: lipofilling, mesh, ADM etc.) could be added.
  • Procedure: Immediate or delayed breast reconstruction — In the standard arm of the PRADAIIBE, the participants will undergo immediate or delayed breast reconstruction surgery. This is defined as breast reconstruction taking place at the same time as oncological surgery (immediate), or at a later time (delayed). Using one of the following primary techniques: 1) Autologous tissue reconstruction ; 2) Breast implant based reconstruction; 3) Combined autologous tissue and breast implant reconstruction. These techniques can take place in a single phase, or in a two-phased (tissue expander) approach. Adjuvant techniques (e.g.: lipofilling, mesh, ADM etc.) could be added.
Study Locations (6 sites)
Universitair Ziekenhuis Antwerpen (UZA), Edegem, Antwerpen 2650 Belgium
Ziekenhuis aan de stroom, Wilrijk, Antwerpen 2610 Belgium
AZ Klina, Brasschaat, Antwerp 2930 Belgium
CHU Namur, Namur, Namur 5000 Belgium
Universitair Ziekenhuis Gent (UZGent), Ghent, Oost Vlaanderen 9000 Belgium
AZ Groeninge, Kortrijk, West Vlaanderen 8500 Belgium
Eligibility Criteria
Screening assessments, including review of all study eligibility criteria must be completed before enrolment and randomisation. Inclusion criteria: In order to be eligible to participate in this study, a participant must meet all of the following criteria: 1\. Women ≥18 years with histopathologically confirmed breast cancer who: 1.a. require SSM/NSM for any reason (e.g. extensive disease) 1.b. require postoperative radiation therapy of at least the chest wall 1. c. have a wish for a breast reconstruction 2. An Eastern Cooperative Oncology Group (ECOG) performance status grade ≤ 2 3. Participant is able and willing to provide written informed consent, which includes compliance with and ability to undergo all study procedures, and attend the scheduled follow-up visit(s) per protocol. Exclusion criteria: A potential participant who meets any of the following criteria will be excluded from participation in this study: 1. A previous history of breast cancer or irradiation of the chest wall for any other indication, on the other side (ipsilateral). A bilateral SSM/NSM + reconstruction (e.g. in case of a contralateral prophylactic SSM/NSM), or previous contralateral breast cancer disease/treatment, do not fall under this criterium and are thus allowed. 2. Collagen synthesis disease 3. Ongoing pregnancy 4. Actively breastfeeding 5. Smoking at time of inclusion (a history of smoking is allowed but needs to be registered in the eCRF). No interval between smoking cessation and study inclusion is defined, but the reconstructive surgeon needs to be willing to operate the patient using autologous tissue transfer. This generally translates to a smoking cessation of \>3months preoperatively. 6. BMI \> 35 kg/m2 7. cT4d tumour, metastatic disease or any reason making SSM/NSM not indicated
Conditions Heart Rate Variability, Stress, Depressi...
Phase NA
Enrollment 76
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to address existing research gaps by investigating the effects of technology-assisted horticultural therapy on stress, depression, and happiness among older adults residing in long-term care facilities. By examining the modulation of the autonomic nervous system, the findings will provide a foundation for developing comprehensive health promotion programs that integrate traditional therapeutic practices with modern technology to enhance the well-being of the aging population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Information Technology-Assisted Horticultural Therapy Program — The intervention involves technology-assisted horticultural therapy sessions conducted once a week, lasting 120 minutes per session, over a total period of 8 weeks

Primary Outcomes

  • Heart Rate Variability, HRV (Baseline, pre-intervention (T0))
  • Perceived Stress Scale, PSS (Baseline, pre-intervention (T0))
  • Geriatric Depression Scale, GDS-15 (Baseline, pre-intervention (T0))
  • The 5-item World Health Organization Well-Being Index, WHO-5 (Baseline, pre-intervention (T0))
  • The efficacy of horticultural therapy evaluation form; EHTE (Baseline, pre-intervention (T0))
  • Heart Rate Variability, HRV (4 weeks after intervention (T1))
  • Perceived Stress Scale, PSS (4 weeks after intervention (T1))
  • Geriatric Depression Scale, GDS-15 (4 weeks after intervention (T1))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-14
Completion: 2026-10-08
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: true
Enrollment: 76 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taipei University of Nursing and Health Sciences
Contact Information
Study Contact:
Jung Chia Hsieh, PhD
+886(2)2822-7101
chiajung@ntunhs.edu.tw
Feng Qiu Hu, BSN
+886-988724682
fany861128@gmail.com
Jung Chia Hsieh, PhD
+886(2)2822-7101
chiajung@ntunhs.edu.tw
National Taipei University of Nursing and Health Sciences
Interventions
  • Other: Information Technology-Assisted Horticultural Therapy Program — The intervention involves technology-assisted horticultural therapy sessions conducted once a week, lasting 120 minutes per session, over a total period of 8 weeks
Study Locations (1 sites)
National Taipei University of Nursing and Health Sciences, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Agree to participate in this study 2. Elderly persons aged 65 and above living in long-term care facilities 3. Live in long-term care facilities for at least three months 4. No gender restrictions 5. Be aware, able to communicate in Mandarin and Taiwanese, and be able to express opinions 6. The upper limbs can move freely and there is no disease that causes tremors in the hands (such as Parkinson's disease, hepatic encephalopathy, etc.) Exclusion Criteria: 1. Has participated in gardening-related activities within one month of receiving the case 2. Those diagnosed with terminal illness or whose health condition is rapidly deteriorating 3. Those suffering from Parkinson's disease, serious heart disease, dementia, mental illness (e.g. schizophrenia, bipolar disorder, etc.) 4. Mini-Mental State Examination (MMSE) with cognitive impairment (MMSE scores below 16 points for individuals with no formal education, below 21 points for those with elementary education, and below 24 points for those with junior high school education or higher.) 5. Those who are unable to participate in the event due to severe speech, vision or hearing impairment
Conditions Elevated Blood Pressure, Hypertension
Phase NA
Enrollment 160
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study will be a multi-center, randomized clinical trial to evaluate the safety and efficacy of using the Zona Plus handgrip therapy device compared to the use of an auditory relaxation therapy for treatment of high blood pressure and hypertension in subjects who are not currently taking antihypertensive medications. Half of the study subjects will also be randomized to record blood pressure at home throughout the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Zona Plus Device — Use of the Zona Plus device involves performing isometric handgrip exercise therapy. Isometric exercise is the type of exercise in which you tense or tighten your muscle without seeing it change in length.
  • Other: Relaxing Music App — Relaxing music will be made available through a mobile app that users access via their smart phone or tablet. Subjects will have the option to listen to 5 different music genres that support relaxation (Classical, Nature, Movie Soundtracks, Jazz, Reggae).

Primary Outcomes

  • Compare the change from baseline in mean seated cuff systolic blood pressure (SBP) after 10 weeks of treatment between patients randomized to the Zona Plus device and the patients in the control group. (10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-27
Completion: 2028-02
Eligibility
Age: 22 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zona Health, Inc
Collaborators: Emergent Clinical Consulting, LLC
Contact Information
Study Contact:
Brandi Caughman
610-454-7200
brandi@emergentcro.com
Mark Young
(888) 804 7993
myoung@ryzeagency.com
Karen Hung
800-831-8308
khhung@bayviewresearch.com
Bayview Research Group
Interventions
  • Device: Zona Plus Device — Use of the Zona Plus device involves performing isometric handgrip exercise therapy. Isometric exercise is the type of exercise in which you tense or tighten your muscle without seeing it change in length.
  • Other: Relaxing Music App — Relaxing music will be made available through a mobile app that users access via their smart phone or tablet. Subjects will have the option to listen to 5 different music genres that support relaxation (Classical, Nature, Movie Soundtracks, Jazz, Reggae).
Study Locations (10 sites)
Bayview Research Group, Valley Village, California 91607 United States
Focus Clinical Research, West Hills, California 91307 United States
Comprehensive Medical & Research, Plantation, Florida 33317 United States
Cedar Crosse Research Center, Chicago, Illinois 60607 United States
Circuit Clinical Grave Gilbert, Bowling Green, Kentucky 42101 United States
Preferred Primary Care Physicians - Pittsburgh, Pittsburgh, Pennsylvania 15243 United States
Preferred Primary Care Physicians - Washington, Washington, Pennsylvania 15301 United States
Community DPC, Cleveland, Tennessee 37312 United States
Zenos Clinical Research, Dallas, Texas 75230 United States
Aavon Clinical Trials, Houston, Texas 77074 United States
Eligibility Criteria
Inclusion Criteria: 1. Subject is male or female age 22 or older 2. Diagnosed with elevated blood pressure or hypertension and verified during Visit #1 by standardized seated cuff SBP 3. Have not taken antihypertensive medication for ≥30 days prior to the SEPV 4. Subject is expected to have sufficient vision, hearing, and hand strength (hand strength is demonstrated by a maximum voluntary contraction (MVC) equaling 35 units of force in both hands measured by a dynamometer 5. Subject has baseline BP measurements collected and completes study device training during Baseline Assessment (Visit #1); 6. Subject agrees to maintain non-use of medications and over-the-counter (OTC) supplement regimen related to hypertension throughout the treatment phase; 7. Patient can comply with and agrees to complete all required study procedures, study clinic visits, and associated activities; 8. Patient must be able to understand and give written informed consent in the language provided; 9. Subject must have SBP of 130 to ≤149 mmHg, if subjects present with SBP reading of ≥140mmHg they will receive heightened monitoring throughout the first month of the study Exclusion Criteria: 1. Subject is a female of childbearing potential (e.g., not postmenopausal for at least one year or has not had a hysterectomy or tubal ligation) not using medically effective birth control (e.g., hormonal methods in use at least 30 days prior to screening or barrier methods such as condom and spermicide in use at least 14 days prior to visit 1) or is pregnant, lactating, or plans to become pregnant during the study). 2. BP ≥150 mmHg (systolic) and/or \>90 mmHg (diastolic) 3. A history of heart failure with current New York Heart Association (NYHA) class III- IV functional classification 4. Currently has, or has had a history, of atrial fibrillation, in accordance with 2007 Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) guidelines 5. Patient has experienced hospitalization due to a hypertensive emergency, with impending or progressive target organ dysfunction (i.e., renal dysfunction, left ventricular hypertrophy or CNS involvement) within the past six (6) months 6. A \>10 mmHg difference in seated cuff SBP between the right and left arms collected during the SEPV; 7. Unstable BP, defined as \>5 mmHg variance between any two (2) consecutive weekly readings (with a maximum of four (4) attempts) to determine a baseline BP measurement ; 8. Arm circumference greater than 45 cm; 9. Acute illness, infection, or inflammation 10. Presence of any unstable cardiovascular disorder, such as MI, unstable angina, significant arrhythmia, stroke, or TIA; within the last six (6) months, or other serious comorbidity that would be likely to impact life expectancy to less than one (1) year or limit patient cooperation or study compliance; 11. A history of rest or exertional angina pectoris in the previous six (6) months; 12. History of solid organ transplant 13. Any secondary form of hypertension (HTN) etiology, including but not limited to primary aldosteronism, chronic steroid therapy and Cushing syndrome, pheochromocytoma, aorta coarctation or untreated thyroid or parathyroid disease; 14. Concurrent participation in an investigational clinical study that has not completed the follow-up period or planned participation in another study within the next six (6) months; 15. Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete, good quality data or the completion of the research study; 16. Patients who currently own or have owned another Zona Plus device and are, or have been, voluntarily performing the isometric handgrip activities. 17. Subject plans for greater than 10% of body weight loss/gain (10% of body weight over a 6-month period) during the study
Conditions Major Depressive Disorder, Recurrent, in...
Phase NA
Enrollment 342
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Objectives: To evaluate the clinical- and cost-effectiveness of two delivery formats of mindfulness-based cognitive therapy (MBCT) - (i) MBCT delivered through eight videoconference group sessions (group MBCT), and (ii) MBCT delivered through a self-help manual plus three low-intensity videoconference group support sessions (supported MBCT self-help) - when added to treatment as usual (TAU; mental health outpatient care), compared with TAU alone, in patients with recurrent depression, either in an acute episode or in remission. We will identify potential predictors and moderators of response and examine psychological mechanisms of change. Study design: Multicentre randomised controlled trial, with pre-post, 6- and 12-months follow-ups. Centres: Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat), Hospital Universitario Miguel Servet (Zaragoza), Hospital del Mar (Barcelona), Fundació Centre Higiene Mental Nou Barris (Barcelona), and Hospital General Universitario de Elche (Elche, Alicante). Participants: Adult patients (n=342) with recurrent depression, either in an acute episode or in remission, will be randomly assigned to group MBCT, supported MBCT self-help, or TAU. Primary outcome: transitions between clinically defined states of recurrent depression over the 12-month follow-up (DSM-5). The primary confirmatory transition is from remission to a major depressive episode (relapse/recurrence), whereas the transition from acute depression to remission will be examined as an exploratory objective. Secondary outcomes: depressive symptom severity, negative affect, mental well-being, quality of life, costs, and quality-adjusted life years. Process measures: mindfulness, positive affect, and self-compassion. Main statistical analyses: The primary analysis will use the intention-to-treat (ITT) principle and continuous-time multi-state modelling to estimate transition-specific hazard ratios. Secondary outcomes, predictors, and moderators will be analysed using regression-based approaches. Cost-effectiveness and cost-utility analyses will be conducted from healthcare system and societal perspectives, alongside mediation analyses. Participant experiences will be evaluated using qualitative methods. Conclusions: This study will inform the implementation of two accessible MBCT formats in Spain for preventing depressive relapse/recurrence. The comparison of two delivery formats will provide evidence on effectiveness, cost-effectiveness, scalability, and efficient resource allocation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Group Mindfulness-Based Cognitive Therapy — Videoconference-delivered group MBCT will be provided in line with the manual 'Mindfulness-Based Cognitive Therapy for Depression'. The program will be led by Spanish MBCT therapists who are trained and certified, and who will also complete a 2-day study standardisation course. After this training, therapists must demonstrate at least "competent" teaching skills, confirmed by an independent assessor using the Mindfulness-Based Interventions Teaching Assessment Criteria (MBI:TAC). Competency will be defined as a score of 4-6 based on the rating of a randomly selected recorded session. Group MBCT is a structured mindfulness meditation program designed to help participants learn skills to reduce the risk of depression relapse or recurrence. It will be delivered over 8 weeks in weekly group sessions lasting 2 hours, with approximately 12 participants per group, and includes between-session home practice.
  • Behavioral: Mindfulness-Based Cognitive Therapy Self-Help — Participants work through the Spanish version of 'The Mindful Way Workbook: An 8-Week Program to Free Yourself from Depression and Emotional Distress' on their own, following weekly instructions and mindfulness exercises. The workbook presents the standard 8-week MBCT program in a self-guided format. It also includes reflection questions, tools to monitor progress, and feedback from people who have previously completed the program. To support engagement and manage difficulties, participants will also take part in three structured, low-intensity group support sessions with a health psychologist (at the start, mid-point, and end of the program). Each session will last 1 hour, be delivered by group videoconference, and include approximately 12 participants per group.
  • Other: Treatment as Usual (TAU) — TAU (treatment as usual) will be delivered as it is in routine clinical practice. In Spain, ongoing care for recurrent depression commonly relies on maintenance antidepressant medication (m-ADM). Spanish National Health System guidelines recommend continuing antidepressants for at least two years at the same dose that was effective during the acute treatment phase. Participants will be advised that, if they notice a worsening of symptoms or encounter difficulties during the study, they should seek help from their primary care General Practitioner or their usual mental health service provider, as they would normally do.

Primary Outcomes

  • Transition from remission to relapse/recurrence, analysed within a continuous-time multi-state model over 12 months (6- and 12-month follow-ups)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-10
Completion: 2028-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 342 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundació Sant Joan de Déu
Collaborators: Carlos III Health Institute, La Caixa Foundation
Principal Investigators:
  • Jesus Montero, PhD (PRINCIPAL_INVESTIGATOR) - Fundació Sant Joan de Déu
Contact Information
Study Contact:
Jesus Montero, PhD
(34) 936 615 208 - 12733
jesus.montero@sjd.es
Jaime Navarrete, PhD
(34) 936 615 208 - 12734
jaime.navarrete@sjd.es
Jose M Rico, Doctor
rico_josgom@gva.es
Hospital General Universitario de Elche
Interventions
  • Behavioral: Group Mindfulness-Based Cognitive Therapy — Videoconference-delivered group MBCT will be provided in line with the manual 'Mindfulness-Based Cognitive Therapy for Depression'. The program will be led by Spanish MBCT therapists who are trained and certified, and who will also complete a 2-day study standardisation course. After this training, therapists must demonstrate at least "competent" teaching skills, confirmed by an independent assessor using the Mindfulness-Based Interventions Teaching Assessment Criteria (MBI:TAC). Competency will be defined as a score of 4-6 based on the rating of a randomly selected recorded session. Group MBCT is a structured mindfulness meditation program designed to help participants learn skills to reduce the risk of depression relapse or recurrence. It will be delivered over 8 weeks in weekly group sessions lasting 2 hours, with approximately 12 participants per group, and includes between-session home practice.
  • Behavioral: Mindfulness-Based Cognitive Therapy Self-Help — Participants work through the Spanish version of 'The Mindful Way Workbook: An 8-Week Program to Free Yourself from Depression and Emotional Distress' on their own, following weekly instructions and mindfulness exercises. The workbook presents the standard 8-week MBCT program in a self-guided format. It also includes reflection questions, tools to monitor progress, and feedback from people who have previously completed the program. To support engagement and manage difficulties, participants will also take part in three structured, low-intensity group support sessions with a health psychologist (at the start, mid-point, and end of the program). Each session will last 1 hour, be delivered by group videoconference, and include approximately 12 participants per group.
  • Other: Treatment as Usual (TAU) — TAU (treatment as usual) will be delivered as it is in routine clinical practice. In Spain, ongoing care for recurrent depression commonly relies on maintenance antidepressant medication (m-ADM). Spanish National Health System guidelines recommend continuing antidepressants for at least two years at the same dose that was effective during the acute treatment phase. Participants will be advised that, if they notice a worsening of symptoms or encounter difficulties during the study, they should seek help from their primary care General Practitioner or their usual mental health service provider, as they would normally do.
Study Locations (5 sites)
Hospital General Universitario de Elche, Elche, Alicante 03203 Spain
Parc de Salut Mar, Barcelona, Barcelona 08003 Spain
Fundacio Centre Higiene Mental Nou Barris, Barcelona, Barcelona Spain
Parc Sanitari Sant Joan de Déu (PSSJD), Sant Boi de Llobregat, Barcelona 08830 Spain
Hospital Universitario Miguel Servet, Zaragoza, Zaragoza 50009 Spain
Eligibility Criteria
Inclusion Criteria: * Age over 18. * Diagnosis of recurrent major depressive disorder, with ≥ 2 previous major depressive episodes (MDD), either in an acute mild/moderate episode or in remission. * Internet access (via smartphone or personal computer). * Spanish literacy (spoken and written). Exclusion Criteria: * Current severe depressive episode (≥24 on the GRID-HAMD) * Current or past psychosis, bipolar 1 disorder, a history of schizophrenia, schizoaffective disorder, organic mental disorder, current severe substance abuse, organic brain damage, pervasive developmental delay, persistent antisocial behaviour, recent (in the past 6 months) self-injury requiring clinical management or therapy according to medical records and clinical judgment. * Formal concurrent structured psychotherapy during the intervention period. * No experience in the use of new technologies (smartphones or computers). * Having completed a mindfulness-based structured training and/or extensive meditation experience (i.e., previous participation in meditation retreats (≥1) or regular (≥ weekly) meditation practice) in the previous year, or intending to commence meditation retreats or meditation practice during the study.
Conditions Locally Advanced Cancer, Metastatic Canc...
Phase EARLY_PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Drug: [68Ga]Ga-ABY-025 — Subjects receive a tracer dose of \[68Ga\]Ga-ABY-025 and will receive a PET/CT scan a few hours after the injection.

Primary Outcomes

  • Determine safety of [68Ga]Ga-ABY-025 PET by assessing for adverse events following the injection and PET imaging. (up to 21± 14 days from second administration of [68Ga]Ga-ABY-025. Assessments will be performed as part of the routine standard of care for patients undergoing HER2-targeted anti-cancer treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2026-04-16
Completion: 2029-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt-Ingram Cancer Center
Contact Information
Study Contact:
Makenna Brown
+1 (615)421-4370
makenna.l.brown@vumc.org
Makenna Brown
+1 (615)421-4370
makenna.l.brown@vumc.org
Vanderbilt University Medical Center
Interventions
  • Drug: [68Ga]Ga-ABY-025 — Subjects receive a tracer dose of \[68Ga\]Ga-ABY-025 and will receive a PET/CT scan a few hours after the injection.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years. 2. Patients with unresectable locally advanced or metastatic cancer who are eligible for standard of care treatment with HER2-targeted therapy per the discretion of their treating physician for an FDA-approved indication. Patients who are planning to start HER2-targeted therapy at the time of study enrollment. Patients who have recently begun HER2 treatment and have received no more than 6 cycles will be eligible for enrollment. 3. Must have a previous biopsy demonstrating HER2 expression in at least one lesion (HER2+ solid cancer, or breast cancer patients who are HER2+ or HER2-low) as defined by IHC and FISH studies or with HER2 amplification as defined by a liquid biopsy that was done as standard of care testing for the patient's cancer type. 4. Measurable disease on CT, FDG-PET, or MRI imaging for RECIST evaluation; patient must have measurable disease outside the liver. 5. Life expectancy of at least 6 months. Patients with brain metastases are permitted to enroll in this study. Exclusion Criteria: 1. Measurable sites of disease only in the liver. 2. Inability to comply with study procedures. 3. Hypersensitivity or allergy to any component of \[68Ga\]Ga-ABY-025. 4. Pregnant or breastfeeding. 5. HER2-negative cancers that have no FDA approved indication for treatment with HER2-directed therapy. 6. Inability to lie flat for 30 minutes during an imaging session. 7. Medical or psychiatric co-morbidities that, in the opinion of the treating physician, would prevent the patient from successfully participating in the study.
Conditions Breast Cancer, Metastatic, Breast Cancer...
Phase NA
Enrollment 93
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Device: The DM/DIV ScreenCell is the experimental product studied during this research — The product is not used directly on the subject, but on a blood sample taken from the participant.

Primary Outcomes

  • Evolution of the kinetics of CTC during treatment (From enrollement to the end of follow up at 9 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-24
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 93 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ScreenCell
Collaborators: AXELYS SANTE
Contact Information
Study Contact:
Jessica GROULT, Ph.D
0033669645318
jgroult@screencell.com
Sina NASERIAN, Ph.D
snaserian@screencell.com
Jean-Michel VANNETZEL, M.D.
CMC Ambroise Paré Hartmann
Interventions
  • Device: The DM/DIV ScreenCell is the experimental product studied during this research — The product is not used directly on the subject, but on a blood sample taken from the participant.
Study Locations (1 sites)
CMC Ambroise Paré Hartmann, Neuilly-sur-Seine, 92200 France
Eligibility Criteria
INCLUSION CRITERIA For all participants : * Female with age greater than or equal to 18 years For participants with metastatic breast cancer: \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion. For participants with non-metastatic invasive breast cancer: \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment) For healthy volunteers: * Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion * Participant with no history of cancer EXCLUSION CRITERIA For all participants: * Male * Age less than 18 years old * Refusal to participate or withdrawal of consent * Pregnant and/or breastfeeding women * Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up. For healthy volunteers: * History of cancer * Detection of CTC (positive profile) during screening